333 related articles for article (PubMed ID: 28797123)
1. Relationship between plasma xanthine oxidoreductase activity and left ventricular ejection fraction and hypertrophy among cardiac patients.
Fujimura Y; Yamauchi Y; Murase T; Nakamura T; Fujita SI; Fujisaka T; Ito T; Sohmiya K; Hoshiga M; Ishizaka N
PLoS One; 2017; 12(8):e0182699. PubMed ID: 28797123
[TBL] [Abstract][Full Text] [Related]
2. Independent association of plasma xanthine oxidoreductase activity with serum uric acid level based on stable isotope-labeled xanthine and liquid chromatography/triple quadrupole mass spectrometry: MedCity21 health examination registry.
Kurajoh M; Fukumoto S; Emoto M; Murase T; Nakamura T; Ishihara T; Go H; Yamamoto K; Nakatani S; Tsuda A; Yamada S; Morioka T; Mori K; Imanishi Y; Inaba M
Clin Chem Lab Med; 2020 Apr; 58(5):780-786. PubMed ID: 31085741
[TBL] [Abstract][Full Text] [Related]
3. Plasma Xanthine Oxidoreductase Activity Associated with Glycemic Control in Patients with Pre-Dialysis Chronic Kidney Disease.
Nakatani S; Ishimura E; Murase T; Nakamura T; Nakatani A; Toi N; Nishide K; Uedono H; Tsuda A; Kurajoh M; Yamada S; Mori K; Inaba M; Emoto M
Kidney Blood Press Res; 2021; 46(4):475-483. PubMed ID: 34082427
[TBL] [Abstract][Full Text] [Related]
4. Association of plasma xanthine oxidoreductase activity with severity and clinical outcome in patients with chronic heart failure.
Otaki Y; Watanabe T; Kinoshita D; Yokoyama M; Takahashi T; Toshima T; Sugai T; Murase T; Nakamura T; Nishiyama S; Takahashi H; Arimoto T; Shishido T; Miyamoto T; Kubota I
Int J Cardiol; 2017 Feb; 228():151-157. PubMed ID: 27865177
[TBL] [Abstract][Full Text] [Related]
5. Xanthine oxidoreductase activity is correlated with insulin resistance and subclinical inflammation in young humans.
Washio KW; Kusunoki Y; Murase T; Nakamura T; Osugi K; Ohigashi M; Sukenaga T; Ochi F; Matsuo T; Katsuno T; Moriwaki Y; Yamamoto T; Namba M; Koyama H
Metabolism; 2017 May; 70():51-56. PubMed ID: 28403945
[TBL] [Abstract][Full Text] [Related]
6. Annual change in plasma xanthine oxidoreductase activity is associated with changes in liver enzymes and body weight.
Furuhashi M; Koyama M; Matsumoto M; Murase T; Nakamura T; Higashiura Y; Tanaka M; Moniwa N; Ohnishi H; Saitoh S; Shimamoto K; Miura T
Endocr J; 2019 Sep; 66(9):777-786. PubMed ID: 31130575
[TBL] [Abstract][Full Text] [Related]
7. Is Serum Uric Acid Independently Associated With Left Ventricular Mass Index, Ejection Fraction, and B-Type Natriuretic Peptide Among Female and Male Cardiac Patients?
Yamauchi Y; Fujita SI; Shibata K; Morita H; Ito T; Sohmiya K; Hoshiga M; Ishizaka N
Int Heart J; 2017 Aug; 58(4):562-569. PubMed ID: 28701671
[TBL] [Abstract][Full Text] [Related]
8. Unexpected high plasma xanthine oxidoreductase activity in female subjects with low levels of uric acid.
Furuhashi M; Mori K; Tanaka M; Maeda T; Matsumoto M; Murase T; Nakamura T; Koyama M; Moniwa N; Ohnishi H; Saitoh S; Shimamoto K; Miura T
Endocr J; 2018 Nov; 65(11):1083-1092. PubMed ID: 30068899
[TBL] [Abstract][Full Text] [Related]
9. Association of the plasma xanthine oxidoreductase activity with the metabolic parameters and vascular complications in patients with type 2 diabetes.
Okuyama T; Shirakawa J; Nakamura T; Murase T; Miyashita D; Inoue R; Kyohara M; Togashi Y; Terauchi Y
Sci Rep; 2021 Feb; 11(1):3768. PubMed ID: 33580173
[TBL] [Abstract][Full Text] [Related]
10. Plasma Xanthine Oxidoreductase Activity as a Novel Biomarker of Metabolic Disorders in a General Population.
Furuhashi M; Matsumoto M; Tanaka M; Moniwa N; Murase T; Nakamura T; Ohnishi H; Saitoh S; Shimamoto K; Miura T
Circ J; 2018 Jun; 82(7):1892-1899. PubMed ID: 29643318
[TBL] [Abstract][Full Text] [Related]
11. Xanthine oxidoreductase activity is associated with serum uric acid and glycemic control in hemodialysis patients.
Nakatani A; Nakatani S; Ishimura E; Murase T; Nakamura T; Sakura M; Tateishi Y; Tsuda A; Kurajoh M; Mori K; Emoto M; Inaba M
Sci Rep; 2017 Nov; 7(1):15416. PubMed ID: 29133805
[TBL] [Abstract][Full Text] [Related]
12. A highly sensitive assay of human plasma xanthine oxidoreductase activity using stable isotope-labeled xanthine and LC/TQMS.
Murase T; Nampei M; Oka M; Miyachi A; Nakamura T
J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Dec; 1039():51-58. PubMed ID: 27816314
[TBL] [Abstract][Full Text] [Related]
13. Independent links between plasma xanthine oxidoreductase activity and levels of adipokines.
Furuhashi M; Matsumoto M; Murase T; Nakamura T; Higashiura Y; Koyama M; Tanaka M; Moniwa N; Ohnishi H; Saitoh S; Shimamoto K; Miura T
J Diabetes Investig; 2019 Jul; 10(4):1059-1067. PubMed ID: 30516339
[TBL] [Abstract][Full Text] [Related]
14. Plasma xanthine oxidoreductase (XOR) activity in patients who require cardiovascular intensive care.
Shibata Y; Shirakabe A; Okazaki H; Matsushita M; Goda H; Shigihara S; Asano K; Kiuchi K; Tani K; Murase T; Nakamura T; Kobayashi N; Hata N; Asai K; Shimizu W
Heart Vessels; 2020 Oct; 35(10):1390-1400. PubMed ID: 32342210
[TBL] [Abstract][Full Text] [Related]
15. Xanthine oxidoreductase activity assay in tissues using stable isotope-labeled substrate and liquid chromatography high-resolution mass spectrometry.
Murase T; Nampei M; Oka M; Ashizawa N; Matsumoto K; Miyachi A; Nakamura T
J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Jan; 1008():189-197. PubMed ID: 26673227
[TBL] [Abstract][Full Text] [Related]
16. A highly sensitive assay for xanthine oxidoreductase activity using a combination of [(13) C2 ,(15) N2 ]xanthine and liquid chromatography/triple quadrupole mass spectrometry.
Murase T; Oka M; Nampei M; Miyachi A; Nakamura T
J Labelled Comp Radiopharm; 2016 May; 59(5):214-20. PubMed ID: 27006202
[TBL] [Abstract][Full Text] [Related]
17. Plasma xanthine oxidoreductase activity in Japanese patients with type 2 diabetes across hospitalized treatment.
Kawachi Y; Fujishima Y; Nishizawa H; Nagao H; Nakamura T; Akari S; Murase T; Taya N; Omori K; Miyake A; Fukuda S; Takahara M; Kita S; Katakami N; Maeda N; Shimomura I
J Diabetes Investig; 2021 Aug; 12(8):1512-1520. PubMed ID: 33211396
[TBL] [Abstract][Full Text] [Related]
18. Xanthine oxidoreductase activity correlates with vascular endothelial dysfunction in patients with type 1 diabetes.
Washio K; Kusunoki Y; Tsunoda T; Osugi K; Ohigashi M; Murase T; Nakamura T; Matsuo T; Konishi K; Katsuno T; Namba M; Koyama H
Acta Diabetol; 2020 Jan; 57(1):31-39. PubMed ID: 31093763
[TBL] [Abstract][Full Text] [Related]
19. B-type natriuretic peptide (BNP) and amino-terminal proBNP in patients with CKD: relationship to renal function and left ventricular hypertrophy.
Vickery S; Price CP; John RI; Abbas NA; Webb MC; Kempson ME; Lamb EJ
Am J Kidney Dis; 2005 Oct; 46(4):610-20. PubMed ID: 16183415
[TBL] [Abstract][Full Text] [Related]
20. Characteristics of Patients with an Abnormally Decreased Plasma Xanthine Oxidoreductase Activity in Acute Heart Failure Who Visited the Emergency Department.
Shirakabe A; Okazaki H; Matsushita M; Shibata Y; Goda H; Shigihara S; Asano K; Tani K; Kiuchi K; Murase T; Nakamura T; Kobayashi N; Hata N; Asai K; Shimizu W
Cardiology; 2020; 145(8):473-480. PubMed ID: 32615578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
